Pembrolizumab Activity in Tyrosine Kinase Inhibitor–Refractory Metastatic GIST : A Case Report
Cancer Reports · 2026-11 · 9 (11)
DOI: 10.1002/cnr2.70726 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Reports, online erschienen am 04.11.2026. Verfasst von Neharika Bandaru und 2 weiteren Autor:innen. Beteiligte Einrichtung: USC Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Protein Kinase Inhibitors, Antibodies, Monoclonal, Humanized, Liver Neoplasms. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Gastrointestinal stromal tumors (GISTs) are commonly driven by activating mutations in KIT or PDGFRA . Although sequential tyrosine kinase inhibitors (TKIs) have improved outcomes in advanced disease, acquired resistance is common. Prospective studies of immune checkpoint blockade in GIST have shown limited activity, and immunotherapy is not a standard treatment. Case Presentation A man diagnosed at age 57 with epithelioid small‐bowel GIST developed hepatic metastatic disease 7 years after his initial diagnosis. His tumor harbored a primary KIT exon 11 D579del mutation, a secondary KIT exon 17 D820G mutation, and CDKN2A/CDKN2B deletions; available molecular testing reported a low tumor mutational burden (1 mutation/Mb) and microsatellite‐stable disease. After progression or treatment‐limiting toxicity during six TKI regimens, pembrolizumab was initiated on October 28, 2025, when he was 76 years old, and administered intravenously every 3 weeks. The treatment has demonstrated stable disease on CT imaging; cycle 13 was then administered on July 28, 2026. No treatment delays or treatment‐related adverse events were reported through cycle 13.
Conclusion
Pembrolizumab was associated with at least 9 months of disease control in TMB‐low, microsatellite‐stable metastatic GIST after six TKI regimens. Because contemporaneous immune profiling and complete historical dosing data were unavailable, this observation is hypothesis‐generating and does not establish that prior TKI exposure sensitized the tumor to PD‐1 blockade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- USC Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
- Department of Internal Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
- Los Angeles General Medical Center, Los Angeles, California, USA.
ORCID-Profile: Neharika Bandaru, Job Shiach, Mark Agulnik
Zitieren
APA
Bandaru, N., Shiach, J., & Agulnik, M. (2026). Pembrolizumab Activity in Tyrosine Kinase Inhibitor–Refractory Metastatic GIST : A Case Report. Cancer Reports, 9(11). https://doi.org/10.1002/cnr2.70726
Vancouver
Bandaru N, Shiach J, Agulnik M. Pembrolizumab Activity in Tyrosine Kinase Inhibitor–Refractory Metastatic GIST : A Case Report. Cancer Reports. 2026;9(11). doi:10.1002/cnr2.70726
BibTeX
@article{Bandaru2026,
author = {Bandaru, Neharika and Shiach, Job and Agulnik, Mark},
title = {Pembrolizumab Activity in Tyrosine Kinase Inhibitor–Refractory Metastatic GIST : A Case Report},
journal = {Cancer Reports},
year = {2026},
volume = {9},
number = {11},
doi = {10.1002/cnr2.70726}
}
EUVIMED